Background Devices that increase the penetration of intravesical chemotherapeutic agents
have been developed as alternatives to the use of bacillus Calmette–Guérin, in short supply …

Non-muscle invasive bladder cancer (NMIBC) is a challenging disease, with a high risk of
recurrence and even progression to muscle invasive disease. The present standard …

Objectives The objectives of the study are to explore tolerability, acceptability and
oncological outcomes for patients with high‐risk non‐muscle‐invasive bladder cancer …

Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder cancer,
accounts for~ 75% of bladder cancer diagnoses. This disease has a 50% risk of recurrence …

Study Type–Therapy (RCT) Level of Evidence 1b What's known on the subject? and What
does the study add? Microwave‐induced hyperthermia and mitomycin C is a device …

Purpose The purpose of the study was to compare the outcomes of high-risk non-muscle-
invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating …

Introduction: Non-muscle invasive bladder cancer (NMIBC) is a frequently diagnosed
neoplasm, which is typically managed with transurethral resection of bladder tumor (TURBT) …

Simple Summary Intravesical instillation using bacillus Calmette-Guérin (BCG) is the
standard therapy for patients with high-risk, non-muscle-invasive bladder cancer. If BCG …

Background Adjuvant intravesical chemotherapy following tumour resection is
recommended for intermediate-risk non–muscle-invasive bladder cancer (NMIBC) …

Aim: Owing to the limited efficacy and significant toxicity of most topical intravesical agents
for the management of nonmuscle invasive bladder cancer (NMIBC), a search for new …